Therapeutic Targeting of FLT3 in Acute Myeloid Leukemia: Current Status and Novel Approaches

FMS-like tyrosine kinase 3 (FLT3) is mutated in approximately 30% of acute myeloid leukemia (AML) patients. The presence of FLT3-ITD (internal tandem duplication, 20–25%) mutation and, to a lesser extent, FLT3-TKD (tyrosine kinase domain, 5–10%) mutation is associated with poorer diagnosis and thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Tecik, Melisa, Adan, Aysun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719701/
https://www.ncbi.nlm.nih.gov/pubmed/36474506
http://dx.doi.org/10.2147/OTT.S384293

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719701/
https://www.ncbi.nlm.nih.gov/pubmed/36474506
http://dx.doi.org/10.2147/OTT.S384293

Ejemplares similares